Inovio Pharmaceuticals (NASDAQ:INO): According to 5 Analysts, The short term target price has been estimated at $ 18.6.The target price could deviate by a maximum of $7.23 from the forecast price. In the near term, the target price could hit a high of $31 and a low of $ 13.
Many analysts have stated their opinion on the company shares. Equity Analysts at the Brean Capital maintains the rating on Inovio Pharmaceuticals (NASDAQ:INO). The brokerage firm has issued a Buy rating on the shares. The Analysts at the ratings agency lowers the price target from $20 per share to $18 per share. The rating by the firm was issued on March 14, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Benito Simon X, director of Inovio Pharmaceuticals, Inc., had unloaded 6,250 shares at an average price of $10.37 in a transaction dated on May 18, 2016. The total value of the transaction was worth $64,813.
Inovio Pharmaceuticals (NASDAQ:INO) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.42 points or 3.95% at $10.2 with 1,283,218 shares getting traded. Post opening the session at $10.52, the shares hit an intraday low of $10.17 and an intraday high of $10.76 and the price was in this range throughout the day. The company has a market cap of $746 million and the number of outstanding shares have been calculated to be 73,097,059 shares. The 52-week high of Inovio Pharmaceuticals (NASDAQ:INO) is $11.69 and the 52-week low is $4.5.
Inovio Pharmaceuticals, Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31, 2014, Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza and Ebola. With its immunotherapy platform consisting of SynCon products, as well as its CELLECTRA electroporation delivery technology, Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovios immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.